Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Study Period: * Estimated date of first patient enrolled: First quarter of 2011 * Anticipated recruitment period: 3 years * Estimated date of last patient completed: First quarter of 2017, follow up to 2022. Treatment duration: Patients will receive intradermal immunization once a week for 4 weeks followed by monthly "vaccine boost" during the first year. Patients that show immunological response will continue with vaccination every month the second and third year or as long as there is vaccine available. The patients will have follow up for 5 years or until progression of disease as evaluated by the investigator.